| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7132570 | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Dec, 2023
(4 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE37516 | CEPHALON | Acetamide derivative having defined particle size |
Oct, 2014
(9 years ago) | |
|
USRE37516 (Pediatric) | CEPHALON | Acetamide derivative having defined particle size |
Apr, 2015
(9 years ago) | |
| US7297346 | CEPHALON | Pharmaceutical formulations of modafinil |
Nov, 2023
(4 months ago) | |
|
US7297346 (Pediatric) | CEPHALON | Pharmaceutical formulations of modafinil |
May, 2024
(a month from now) | |
|
US7132570 (Pediatric) | CEPHALON | Method for the production of crystalline forms and crystalline forms of optical enantiomers of modafinil |
Jun, 2024
(a month from now) | |
Nuvigil is owned by Cephalon.
Nuvigil contains Armodafinil.
Nuvigil has a total of 6 drug patents out of which 4 drug patents have expired.
Expired drug patents of Nuvigil are:
- USRE37516
- USRE37516*PED
- US7297346
- US7132570
Nuvigil was authorised for market use on 15 June, 2007.
Nuvigil is available in tablet;oral dosage forms.
Nuvigil can be used as improved wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder.
The generics of Nuvigil are possible to be released after 18 June, 2024.
Drugs and Companies using ARMODAFINIL ingredient
Market Authorisation Date: 15 June, 2007
Treatment: Improved wakefulness in patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder
Dosage: TABLET;ORAL
NUVIGIL family patents
